ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AbbVie seeks EMA approval for risankizumab (Skyrizi) to treat moderate to severe Crohn’s disease
December 02, 2021AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to... -
Risankizumab induces deep remissions in Crohn’s disease trial
June 04, 2021Phase III trial data shows more than half of patients with moderate to severe Crohn’s disease treated with risankizumab (Skyrizi®) 360mg achieved clinical remission in a year. -
Risankizumab trials show higher clinical remission in patients with Crohn’s disease
January 12, 2021Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn’s disease. -
NICE recommends risankizumab to treat severe psoriasis
July 15, 2019NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis. -
AbbVie files risankizumab in the US
April 28, 2018AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.
Pharma Sources Insight January 2025
